The drug Omacor has been approved for the treatment of post-infarct patients. The drug, that is developed by the Norsk Hydro subsidiary Pronova, will soon be launched in several European countries. A large clinical study concluded that Omacor reduced mortality in the treatment group by 20 per cent. Omacor has been approved for the treatment of post-infarct patients in the UK, Germany, France, Austria and Greece. Applications for approval will be filed in a number of other countries. The Norwegian authorities are expected to approve the drug this spring.
Omacor was developed at Norsk Hydro's Research Center in Porsgrunn. It is the first therapeutic drug ever developed in Norway. Pronova Biocare has entered into an agreement with the French pharmaceutical company Pierre Fabre for the marketing and sale of Omacor in France.